The #ASH24 abstracts are live! See the amazing scientific breakthroughs being presented at the ASH annual meeting. View them now: ow.ly/szvb50U0j7Y Experience the science in San Diego or virtually. Registration is still open!

Great study of irMyocarditis nature, which appears to be mediated by DCs, cycling CD8 T cells and CXCR3-L expressing fibroblast subsets in the tissue. Interestingly, expanded T cell clones were shared between blood and heart but not the tumor. Many more important insights 👀

Important observation, highlighting the need to not only reduce radiotherapy but also anthracycline exposure in (Hodgkin) lymphoma treatment. Need to tailor treatment to individual risk and re-evaluate cardioprotective measures.

Delighted to share the practice-changing #STARGLO study manuscript at The Lancet today. Transplant-ineligible DLBCL should no longer be considered a palliative scenario #lymsm Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-G... sciencedirect.com/science/articl…

Just out JAMA Oncology led by ErfanParsa We review why many efforts to improve access to oncology medicines around the world have failed so far, especially compared to infectious diseases, & offer potential strategies to improve global pharmacoequity jamanetwork.com/journals/jamao…

Really looking forward to contributing to the first UK Hodgkin Lymphoma forum in February 2025. Exciting times with a lot of opportunities for collaboration for the benefit of our patients.

⭐️NEW PAPER OUT in nature⭐️ 🫀What is the relationship between the immune responses in the heart, blood, and tumor in patients with inflammation in the heart resulting from cancer immunotherapy (irMyocarditis)? This 🧵 breaks down the key findings 1/n nature.com/articles/s4158…

In the dose escalation phase of the ongoing #LIBRA4Trial, patients with relapsed/refractory peripheral T cell #lymphoma were treated with TRBC1-targeted CAR #TCellTherapy, showing limited toxicity and promising early clinical responses. nature.com/articles/s4159…

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results: nej.md/4eGp1tj

Congrats, Petra and whole #DCLLSG study team Michael Hallek Uniklinik Köln! Great to finally see this important data published Journal of Clinical Oncology

How do ageing and age-associated changes of the immune landscape affect immunotherapies in patients with lymphoma or multiple myeloma? Very happy to see our comprehensive review of the available evidence lead by Fabian Ullrich & Nina Rosa Neuendorff out Journal for ImmunoTherapy of Cancer 🎉 jitc.bmj.com/content/12/12/…

Nice real-world data on the safety and efficacy of low-dose nivolumab from Monterrey 🇲🇽 Similarly high response rates and survival with lower doses of 40-140mg Q2W instead of 240mg in the pivotal CM205 study in this single-center cohort (N=27): tinyurl.com/569krdzb

Happy to be back in San Diego for #ASH24🩸🌞🌴🌮 Looking forward to a lot of exciting science, impactful data and exchange with international colleagues and friends

CONGRESS | #ASH24 | Justin Ferdinandus Justin Ferdinandus Uniklinik Köln shares results from the phase II portion of the GHSG HD21 trial of PET-guided BrECADD in older patients with advanced-stage cHL. At a median FU of 23 mo, 12 mo PFS 95.1%, 24 mo PFS 91.5, 12 mo OS 96.2%, 24 mo OS

🚨 HOT OFF THE PRESS!! Impact of immunological #aging on T cell-mediated therapies in older adults 👴👵 with multiple #myeloma and #lymphoma #hematology 🩸 #lymsm #mmsm #ImmunoOnc search.app/vHF2CdrQUKDVq3…

Catch up on our panel discussion on sequencing targeted therapies for cHL, chaired by @gilles_salles, Memorial Sloan Kettering Cancer Center, and joined by Ann LaCasce, MD, Harvard Medical School, and Paul Bröckelmann, Uniklinik Köln. Watch the full video here: loom.ly/G_SLHdI #lymsm #MedEd #ESHLYMPHOMA2024

Congrats to Nicole Seifert Uni Göttingen & Wolfram Klapper Universitätsklinikum Schleswig-Holstein who spearheaded our TCRseq study in Hodgkin lymphoma Leukemia Journal. Exclusion of clonally expanded T-cells from the TME as a mechanism of immune evasion during anti-PD1 treatment? nature.com/articles/s4137…

📄📣 Analyzing >10,000 patients treated in randomized GHSG trials, we show strong correlation of PFS and OS after Hodgkin lymphoma first-line treatment across risk groups Annals of Oncology doi.org/10.1016/j.anno…! Great GHSG team effort Bastian von Tresckow Uniklinikum Essen Uniklinik Köln 🎉

Thanks for the shout-out and support, Raul Cordoba, MD, PhD! Grateful European Hematology Association for the opportunity to strengthen European collaboration and gain further insights into the biology of Hodgkin lymphoma in older patients to explore novel therapeutic approaches. 🩸🧫🧑‍🔬🇪🇺